|

Ribupatide Clinical Trials

1 actively recruiting trial across 1 location

Also known as: KAI-9531

Pipeline

Phase 3: 1

Top Sponsors

  • Kailera1

Indications

  • Overweight With Diabetes1
  • Obesity With Diabetes1
  • Diabetes1

Cullman, Alabama1 trial

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera Clinical Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.